In his inaugural post, Mr. Kling introduces Protalex’s lead product candidate, PRTX-100, and highlights the Company’s upcoming milestones. “We are very excited for the second half of 2015, as we expect it to be a period of significant progress as we work diligently to develop PRTX-100 efficiently and effectively along several fronts,” wrote Kling. Read the full blog post from Mr. Kling on TheChairmansBlog.com (http://www.thechairmansblog.com/protalex/arnold-kling/potential-new-treatment-option-for-rheumatoid-arthritis-immune-thrombocytopenia-and-other-auto-immune-diseases/).
About Protalex, Inc.
Protalex, Inc. is a clinical-stage biopharmaceutical company focused on the development of a class of drugs for treating autoimmune and inflammatory diseases including Rheumatoid Arthritis (RA) and Immune Thrombocytopenia (ITP). Protalex’s lead product, PRTX-100, is a formulation of a proprietary, highly purified form of Staphylococcal Protein A, which is an immunomodulatory protein produced by bacteria. PRTX-100 has the ability, at very low concentrations, to bind to human B-lymphocytes and macrophages and to modulate immune processes. The safety, tolerability and pharmacokinetics of PRTX-100 have been characterized in five clinical studies. In two Phase 1b clinical trials in adult patients with active RA, PRTX-100 was generally safe and well tolerated at all dose levels, and at certain higher doses, more patients showed improvement in measures of RA disease activity than did patients at the lower dose or placebo cohorts.
TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com.